Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: E-2012
  • Price: $650.0/100mg $1200.0/250mg $2200.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

870843-42-8

870843-42-8 structure
870843-42-8 structure
  • Name: E 2012
  • Chemical Name: (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one
  • CAS Number: 870843-42-8
  • Molecular Formula: C25H26FN3O2
  • Molecular Weight: 419.49100
  • Catalog: Signaling Pathways Neuronal Signaling γ-secretase
  • Create Date: 2018-12-25 17:55:08
  • Modify Date: 2024-01-02 17:08:07
  • E 2012 is a potent γ-secretase modulator.IC50 value:Target: γ-secretaseIn the present study, 9 dogs were treated with a single dose of the γ-secretase modulator E2012, the γ-secretase inhibitor LY450139, or vehicle with a dosing interval of 1 week. The isoform Aβ(1-37) was significantly increased in a dose-dependent manner in response to treatment with E2012, while Aβ(1-39), Aβ(1-40) and A(1-42) decreased [1].E2012, a gamma secretase modulator without affecting Notch processing, aimed at Alzheimer's disease by reduction of amyloid β-42, induced cataract following repeated doses in the rat.E2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. In vivo lenticular concentration of E2012 after 13-week repeated dose with cataract was well above those where inhibition was observed in vitro.E2012 induces cataract in the rat by inhibiting DHCR24 at the final step of cholesterol synthesis with associated elevation in desmosterol within the lens, preceded by desmosterol changes that would serve as a predictive safety biomarker for lenticular opacity [2].

Name (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one
Synonyms (S,E)-1-(1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)piperidin-2-one
(3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one
E-2012
(e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one
cc-582
E 2012
Description E 2012 is a potent γ-secretase modulator.IC50 value:Target: γ-secretaseIn the present study, 9 dogs were treated with a single dose of the γ-secretase modulator E2012, the γ-secretase inhibitor LY450139, or vehicle with a dosing interval of 1 week. The isoform Aβ(1-37) was significantly increased in a dose-dependent manner in response to treatment with E2012, while Aβ(1-39), Aβ(1-40) and A(1-42) decreased [1].E2012, a gamma secretase modulator without affecting Notch processing, aimed at Alzheimer's disease by reduction of amyloid β-42, induced cataract following repeated doses in the rat.E2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. In vivo lenticular concentration of E2012 after 13-week repeated dose with cataract was well above those where inhibition was observed in vitro.E2012 induces cataract in the rat by inhibiting DHCR24 at the final step of cholesterol synthesis with associated elevation in desmosterol within the lens, preceded by desmosterol changes that would serve as a predictive safety biomarker for lenticular opacity [2].
Related Catalog
References

[1]. Nakano-Ito K, et al. E2012-induced cataract and its predictive biomarkers. Toxicol Sci. 2014 Jan;137(1):249-58.

[2]. Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K.Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.J Alzheimers Dis. 2010;21(3):1005-12.

Density 1.195g/cm3
Boiling Point 649.168ºC at 760 mmHg
Molecular Formula C25H26FN3O2
Molecular Weight 419.49100
Flash Point 346.405ºC
Exact Mass 419.20100
PSA 47.36000
LogP 5.03330
Index of Refraction 1.6

~88%

870843-42-8 structure

870843-42-8

Literature: Eisai RandD Management Co., Ltd. Patent: EP1950211 A1, 2008 ; Location in patent: Page/Page column 64 ;

~%

870843-42-8 structure

870843-42-8

Literature: EP1953151 A1, ; Page/Page column 13 ;

~82%

870843-42-8 structure

870843-42-8

Literature: Eisai RandD Management Co., Ltd. Patent: EP1950211 A1, 2008 ; Location in patent: Page/Page column 62 ;

~88%

870843-42-8 structure

870843-42-8

Literature: Eisai RandD Management Co., Ltd. Patent: US2008/306272 A1, 2008 ; Location in patent: Page/Page column 8; 9 ;

~58%

870843-42-8 structure

870843-42-8

Literature: Eisai RandD Management Co., Ltd. Patent: EP1950211 A1, 2008 ; Location in patent: Page/Page column 60 ;

~%

870843-42-8 structure

870843-42-8

Literature: EP1950211 A1, ; Page/Page column 52-53 ;

~%

870843-42-8 structure

870843-42-8

Literature: EP1950211 A1, ; Page/Page column 56-57 ;

~%

870843-42-8 structure

870843-42-8

Literature: EP1950211 A1, ; Page/Page column 58-59 ;

~76%

870843-42-8 structure

870843-42-8

Literature: Eisai RandD Management Co., Ltd. Patent: EP1950211 A1, 2008 ; Location in patent: Page/Page column 64 ;
Precursor  3

DownStream  0